G. Rocamora

A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID)

C. Tebé, M. Gasa, S. Videla, 2022, Trials.

Effect of an awareness campaign on the diagnosis and clinical impact of primary immunodeficiency.

I. Casas, M. Pedro-Botet, N. Sopena, 2020, Medicina clínica (Ed. impresa).

Cannabis use is associated with monocyte activation (sCD163) in patients admitted for alcohol use disorder treatment.

J. Tor, D. Fuster, R. Muga, 2020, Drug and alcohol dependence.

Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial

X. Solanich, F. Llopis, J. Jacob, 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of an awareness campaign on the diagnosis and clinical impact of primary immunodeficiency

I. Casas, M. Pedro-Botet, N. Sopena, 2021 .